47.48

0.02% 0.010

After Hours: 47.50 0.02 +0.04%

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $47.48, with a volume of 3.68M. It is up +0.02% in the last 24 hours and up +10.50% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$47.47

Open:

$46.88

24h Volume:

3.68M

Relative Volume:

0.98

Market Cap:

$20.34B

Revenue:

$2.35B

Net Income/Loss:

$1.30B

P/E Ratio:

27.15

EPS:

1.7487

Net Cash Flow:

$1.05B

1W Performance:

+4.58%

1M Performance:

+10.50%

6M Performance:

+29.51%

1Y Performance:

+40.22%

1-Day Range:

$46.44

$47.66

1-Week Range:

$44.88

$47.66

52-Week Range:

$29.66

$47.66

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1108)

Industry

Biotechnology (620)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

100

Twitter

Next Earnings Date

2026-02-11

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	47.48	20.34B	2.35B	1.30B	1.05B	1.7487
VRTX Vertex Pharmaceuticals Inc	474.27	123.47B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	766.66	83.60B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.72	46.83B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	318.65	43.11B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.04	34.79B	5.36B	287.73M	924.18M	2.5229

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Upgrade	UBS	Neutral → Buy
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

Mar 03, 2026

TD Asset Management Inc Acquires 91,136 Shares of Royalty Pharma PLC $RPRX - MarketBeat

Mar 03, 2026

Quantbot Technologies LP Makes New $2.82 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat

Mar 03, 2026

Mitsubishi UFJ Asset Management Co. Ltd. Buys 44,289 Shares of Royalty Pharma PLC $RPRX - MarketBeat

Mar 03, 2026

Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule - Finviz

Mar 03, 2026

Mar 02, 2026

Royalty Pharma Appoints Kenneth Sun as Senior VP and Head of Asia - National Today

Mar 02, 2026

Affiliated holders sell large RPRX stakes (RPRX) in Feb 2026 trades - Stock Titan

Mar 02, 2026